Lumens Bios루멘스바이오스
038060 · KOSDAQ · ₩038060 · 루멘스바이오스
₩795▲ ₩7 (0.89%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 10.4% | 10.3% | 13.4% | 12.5% | 14.8% | 16.0% |
| Operating margin | −2.9% | −2.9% | −0.9% | 1.6% | 0.7% | 0.5% |
| Net margin | −0.5% | −3.8% | 5.1% | 2.3% | 9.6% | −15.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −6.7% | +0.8% | +1.7% | +3.0% | −3.5% | — |
| Operating income growth | +6.5% | −210.2% | −159.1% | +130.4% | +50.5% | — |
| Net income growth | +88.6% | −175.3% | +120.6% | −74.8% | +158.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −0.7% | −6.1% | 8.4% | 4.2% | 19.0% | −37.1% |
| Return on assets | −0.5% | −4.1% | 5.6% | 2.8% | 9.9% | −16.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 40.8% | 47.4% | 51.0% | 49.7% | 46.9% | 147.6% |
| Net debt to equity | −56.9% | −56.3% | −40.9% | −51.9% | −31.7% | −9.2% |
| Current ratio | 354.2% | 306.8% | 279.7% | 261.8% | 294.9% | 127.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Lumens Bios / 루멘스바이오스 / 038060 / KRX:038060
Source: KRX statistical information